Skip to main contentSkip to navigationSkip to search
Curasight

Transaction with shares in Curasight A/S made by managerial employee

September 3, 2025

Regulatory

Copenhagen, Denmark, 3 September 2025 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transaction made in Curasight made by managerial employee. 

The Company’s managerial employee have given Curasight power of attorney on her behalf to publish sales of Curasight shares as managerial employee conducted 1 September 2025.

The transaction comprise the following managerial employee;

Name Position Aggregated volume Price, DKK
Lars Trolle Deputy Chair of the Board of directors 50,000 226,210.10
Total 50.000 226,210.10

Lars Trolle total holdings in Curasight A/S after the sales of the shares is 591,510 shares.

For further information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: [email protected]

www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.